Buruli ulcer in West Africa: strategies for early detection and treatment in the antibiotic era
- PMID: 20000019
- DOI: 10.4314/eajph.v6i2.51744
Buruli ulcer in West Africa: strategies for early detection and treatment in the antibiotic era
Abstract
Objective: Buruli ulcer (BU), caused by Mycobacterium ulcerans infection, has become one of the most rapidly emerging diseases in West Africa in recent decades. Until recently, the definitive treatment involved wide surgical excision. Recent data suggest that antibiotic therapy with rifampin and streptomycin may reduce the extent or prevent excision when initiated during the early phases of the disease. New strategies for BU control are needed, emphasizing early detection and increasing public awareness about the disease and treatment. Here we review current knowledge about BU and examine clinical, public health and anthropological research in the context of this new treatment paradigm to identify potential strategies for more effective control of this disease.
Methods: A comprehensive literature search for articles in English or French using the Medline and INIST databases, World Health Organization publications, and bibliographical references was undertaken using key words Buruli ulcer. Mycobacterium ulcerans, community surveillance, and public health.
Conclusion: Studies to identify factors contributing to delayed presentation indicate that awareness of the disease is generally good in endemic regions, but wide variation exists in perceived cause of the disease, and the role of sorcery in its transmission and treatment. The use of traditional healers as first line therapy also contributes to delayed treatment, as do lack of awareness about the availability of effective treatment and financial concerns. Epidemiological data from existing BU control programs indicate that active public awareness campaigns are succcessful in increasing understanding and decreasing treatment delay and disease progression. Community-based surveillance and health education modeled after the village health worker programs used in the eradication of Guinea worm may be successfully applied in BU endemic areas.
Similar articles
-
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101. Future Microbiol. 2011. PMID: 22004037 Free PMC article. Review.
-
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).PLoS Negl Trop Dis. 2010 Jul 6;4(7):e736. doi: 10.1371/journal.pntd.0000736. PLoS Negl Trop Dis. 2010. PMID: 20625556 Free PMC article.
-
Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.J Clin Microbiol. 2018 Mar 26;56(4):e01507-17. doi: 10.1128/JCM.01507-17. Print 2018 Apr. J Clin Microbiol. 2018. PMID: 29343539 Free PMC article. Review.
-
Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).Antimicrob Agents Chemother. 2007 Nov;51(11):4029-35. doi: 10.1128/AAC.00175-07. Epub 2007 May 25. Antimicrob Agents Chemother. 2007. PMID: 17526760 Free PMC article. Clinical Trial.
-
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.Antimicrob Agents Chemother. 2014;58(2):1161-6. doi: 10.1128/AAC.02165-13. Epub 2013 Dec 9. Antimicrob Agents Chemother. 2014. PMID: 24323473 Free PMC article.
Cited by
-
Methods and Approaches for Buruli Ulcer Surveillance in Africa: Lessons Learnt and Future Directions.Methods Mol Biol. 2022;2387:87-102. doi: 10.1007/978-1-0716-1779-3_10. Methods Mol Biol. 2022. PMID: 34643905 Review.
-
The contribution of community health workers to the control of Buruli ulcer in the Ngoantet area, Cameroon.Pan Afr Med J. 2013 Oct 22;16:63. doi: 10.11604/pamj.2013.16.63.1407. eCollection 2013. Pan Afr Med J. 2013. PMID: 24711863 Free PMC article.
-
Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.PLoS Negl Trop Dis. 2015 Sep 22;9(9):e0004046. doi: 10.1371/journal.pntd.0004046. eCollection 2015 Sep. PLoS Negl Trop Dis. 2015. PMID: 26393347 Free PMC article.
-
Community-based surveillance: A scoping review.PLoS One. 2019 Apr 12;14(4):e0215278. doi: 10.1371/journal.pone.0215278. eCollection 2019. PLoS One. 2019. PMID: 30978224 Free PMC article.
-
Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.Clin Microbiol Rev. 2017 Dec 13;31(1):e00045-17. doi: 10.1128/CMR.00045-17. Print 2018 Jan. Clin Microbiol Rev. 2017. PMID: 29237707 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical